Advanced in Peripheral T-Cell Lymphoma

Juraj Duras

Ostrava, MO, CZ 
Advanced in Peripheral T-Cell Lymphoma
Ostrava, MO, CZ 
OverviewLocationsClinical Research

Overview

Juraj Duras practices in Ostrava, Czech Republic. Duras is rated as an Advanced expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. Their top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Peripheral T-Cell Lymphoma, T-Cell Lymphoma, and Orchiectomy.

Their clinical research consists of co-authoring 24 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles and participated in 1 clinical trial in the study of Peripheral T-Cell Lymphoma.

Locations

Ostrava, MO, Czech Republic
Other Locations
Hradec Kralove, KR, Czech Republic
Ceske Budejovice, JC 37005, Czech Republic

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
Enrollment Status: Active_not_recruiting
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Study Phase: Phase 2
Midline Programme - Vascular Nursing Team
Midline Programme - Vascular Nursing Team
Enrollment Status: Completed
Publish Date: October 06, 2020
Intervention Type: Device
View 1 Less Clinical Trial

24 Total Publications

Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results.
Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results.
Journal: Hematological oncology
Published: July 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Duras's expertise for a condition
ConditionClose
      View All 20 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile